Predictive assays for craniofacial malformations: evaluation in Xenopus laevis embryos exposed to triadimefon.
Alternative animal model
BMD approach
Craniofacial defects
R-FETAX
Journal
Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
09
05
2022
accepted:
01
06
2022
pubmed:
25
6
2022
medline:
9
8
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Craniofacial defects are one of the most frequent abnormalities at birth, but their experimental evaluation in animal models requires complex procedures. The aim of the present work is the comparison of different methodologies to identify dose- and stage-related craniofacial malformations in Xenopus laevis assay (R-FETAX, where the full cartilage evaluation, including flat mount technique, is the gold standard for skeletal defect detection). Different methods (external morphological evaluation of fresh samples, deglutition test, whole mount cartilage evaluation and Meckel-palatoquadrate angle measurements) were applied. Triadimefon (FON) was selected as the causative molecule as it is known to induce craniofacial defects in different animal models, including the amphibian X. laevis.FON exposure (0-31.25 μM) was scheduled to cover the whole 6-day test (from gastrula to free swimming tadpole stage) or each crucial developmental phases: gastrula, neurula, early morphogenesis, late morphogenesis, tadpole. Dose-dependent effects (fusions among craniofacial cartilages) were evident for groups exposed during the morphogenetic periods (neurula, early morphogenesis, late morphogenesis); gastrula was insensitive to the tested concentrations, tadpole group showed malformations only at 31.25 μM. The overall NOAEL was set at 3.9 μM. Results were evaluated applying benchmark dose (BMD) approach. The comparison of relative potencies from different methods showed deglutition as the only assay comparable with the gold standard (cartilage full evaluation).In conclusion, we suggest deglutition test as a reliable method for a rapid screening of craniofacial abnormalities in the alternative model X. laevis. This is a rapid, inexpensive and vital test allowing to preserve samples for the application of further morphological or molecular investigations.
Identifiants
pubmed: 35748892
doi: 10.1007/s00204-022-03327-w
pii: 10.1007/s00204-022-03327-w
pmc: PMC9352603
doi:
Substances chimiques
Triazoles
0
triadimefon
1HW039CJF0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2815-2824Subventions
Organisme : Università degli Studi di Milano
ID : Linea2_2017
Informations de copyright
© 2022. The Author(s).
Références
Birth Defects Res B Dev Reprod Toxicol. 2011 Jun;92(3):189-94
pubmed: 21594970
Birth Defects Res B Dev Reprod Toxicol. 2005 Apr;74(2):185-95
pubmed: 15834900
Reprod Toxicol. 2011 Sep;32(2):220-6
pubmed: 21601633
Reprod Toxicol. 2011 May;31(4):486-93
pubmed: 21272633
Reprod Toxicol. 2002 Nov-Dec;16(6):815-23
pubmed: 12401511
Food Chem Toxicol. 2020 Mar;137:111117
pubmed: 31927004
Environ Pollut. 2021 Oct 1;286:117541
pubmed: 34118758
Aquat Toxicol. 2005 Jul 30;73(4):370-81
pubmed: 15992940
Toxicology. 2021 Jun 30;458:152843
pubmed: 34186166
Genet Med. 2020 Oct;22(10):1682-1693
pubmed: 32475986
Int J Mol Sci. 2017 Apr 12;18(4):
pubmed: 28417904
Birth Defects Res B Dev Reprod Toxicol. 2011 Feb;92(1):77-81
pubmed: 21254369
PLoS One. 2017 Sep 28;12(9):e0185729
pubmed: 28957438
Dev Dyn. 2005 Dec;234(4):858-67
pubmed: 16222714
Reprod Toxicol. 2022 Jan;107:140-149
pubmed: 34923091
Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):2-11
pubmed: 17187389
Reprod Toxicol. 2020 Sep;96:114-127
pubmed: 32553615
Curr Pathobiol Rep. 2017 Mar;5(1):79-92
pubmed: 28255527
Lancet. 2009 Nov 21;374(9703):1773-85
pubmed: 19747722
Chemosphere. 2018 Aug;204:523-534
pubmed: 29684872
Toxicol Rep. 2020 Apr 19;7:510-519
pubmed: 32346517
Development. 2000 Dec;127(24):5367-78
pubmed: 11076758
EFSA J. 2017 Jan 24;15(1):e04658
pubmed: 32625254
Gene Expr Patterns. 2007 Jan;7(1-2):137-42
pubmed: 16875885
Arch Toxicol. 2018 Dec;92(12):3549-3564
pubmed: 30288550
Crit Rev Toxicol. 2003;33(5):505-42
pubmed: 14594105
Development. 2002 Jan;129(2):421-32
pubmed: 11807034
Toxicol Appl Pharmacol. 2011 Jul 15;254(2):181-91
pubmed: 21034758
Reprod Toxicol. 2011 Feb;31(2):194-9
pubmed: 21055463